In another study, GBM tissues obtained from patients after receiving standard-of-care (maximal safe resection followed by radiotherapy/concomitant and maintenance temozolomide chemotherapy) and bevacizumab monotherapy upon tumor recurrence, exhibit high Bcan expression with no significant difference between the ‘poor’ or ‘better’ prognostic group [39]. The gene discussed is BCAN; the disease is glioblastoma.